Laying The Groundwork For Value-Based Healthcare In Europe
Elisabeth Aloy and David Pistor, healthcare and life sciences advisors at Monitor Deloitte, outline five design principles to create a value-based care project.
You may also be interested in...
US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.
Including the impact on hospitalizations in the label for Novartis's heart failure drug Entresto was critical to enable execution of outcome-based agreements. Such deals present an opportunity for pharma and payers to work together, but many challenges remain.
Performance-based reimbursement agreements with US payers, like the deals that Novartis AG recently struck with Cigna Corp. and Aetna Inc. for the heart failure drug Entresto (sacubitril/valsartan), are rare, but Novartis US Head Christi Shaw said she's hopeful that the concept will catch on.